JP2023511956A5 - - Google Patents

Info

Publication number
JP2023511956A5
JP2023511956A5 JP2022544815A JP2022544815A JP2023511956A5 JP 2023511956 A5 JP2023511956 A5 JP 2023511956A5 JP 2022544815 A JP2022544815 A JP 2022544815A JP 2022544815 A JP2022544815 A JP 2022544815A JP 2023511956 A5 JP2023511956 A5 JP 2023511956A5
Authority
JP
Japan
Prior art keywords
antibody
influenza
drug conjugate
compound
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022544815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511956A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/014802 external-priority patent/WO2021151031A1/en
Publication of JP2023511956A publication Critical patent/JP2023511956A/ja
Publication of JP2023511956A5 publication Critical patent/JP2023511956A5/ja
Pending legal-status Critical Current

Links

JP2022544815A 2020-01-24 2021-01-23 タンパク質－抗ウイルス化合物コンジュゲート Pending JP2023511956A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062965735P 2020-01-24 2020-01-24
US62/965,735 2020-01-24
US202063094285P 2020-10-20 2020-10-20
US63/094,285 2020-10-20
PCT/US2021/014802 WO2021151031A1 (en) 2020-01-24 2021-01-23 Protein-antiviral compound conjugates

Publications (2)

Publication Number Publication Date
JP2023511956A JP2023511956A (ja) 2023-03-23
JP2023511956A5 true JP2023511956A5 (https=) 2024-02-01

Family

ID=74626243

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022544815A Pending JP2023511956A (ja) 2020-01-24 2021-01-23 タンパク質－抗ウイルス化合物コンジュゲート

Country Status (14)

Country Link
US (2) US11752214B2 (https=)
EP (1) EP4093440A1 (https=)
JP (1) JP2023511956A (https=)
KR (1) KR20220131266A (https=)
CN (1) CN115348874A (https=)
AU (1) AU2021210987A1 (https=)
BR (1) BR112022014278A2 (https=)
CA (1) CA3168496A1 (https=)
CL (1) CL2022001970A1 (https=)
CO (1) CO2022011183A2 (https=)
IL (1) IL294989A (https=)
MX (1) MX2022008901A (https=)
PH (1) PH12022551810A1 (https=)
WO (1) WO2021151031A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3220081A1 (en) * 2021-07-28 2023-02-02 Thomas Nittoli Protein-antiviral compound conjugates
AU2023208050A1 (en) * 2022-01-14 2024-07-04 Regeneron Pharmaceuticals, Inc. Verrucarin a derivatives and antibody drug conjugates thereof
CN119528936B (zh) * 2024-11-22 2025-10-17 深圳安泰维生物医药有限公司 一种巴洛沙韦衍生物及其用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136019A (en) * 1989-05-24 1992-08-04 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7102999B1 (en) * 1999-11-24 2006-09-05 Juniper Networks, Inc. Switching device
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
EP1747233A4 (en) 2004-05-06 2007-04-25 COMPOUNDS FOR SPECIFIC VIRAL TARGET
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
EP2167963B1 (en) 2007-05-23 2019-04-17 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
CN110078789A (zh) 2011-05-27 2019-08-02 Ambrx 公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
BR112014009070B1 (pt) 2011-10-14 2021-11-23 Medimmune Limited Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas
CN103997893B (zh) 2011-10-14 2019-04-12 西雅图基因公司 吡咯并苯并二氮杂卓和靶向结合物
EP2751111B1 (en) 2011-10-14 2017-04-26 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
CN105142672B (zh) 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
JP6847388B2 (ja) 2013-03-15 2021-03-31 レゲネロン ファーマシューティカルス，インコーポレーテッド 生物活性分子、そのコンジュゲート、及び治療用途
US9260182B2 (en) * 2013-10-30 2016-02-16 Westjet Airlines Ltd. Integrated communication and application system for aircraft
LT3068776T (lt) * 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
JP6712428B2 (ja) * 2014-02-04 2020-06-24 コントラフェクト コーポレイション インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
US10639370B2 (en) * 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
TW201620932A (zh) * 2014-03-27 2016-06-16 建南德克公司 抗－ｂ型流感病毒血球凝集素抗體及其使用方法
US20160175224A1 (en) * 2014-12-19 2016-06-23 Johnson & Johnson Consumer Companies, Inc. Antiperspirant composition
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
SG11201708721XA (en) * 2015-04-28 2017-11-29 Shionogi & Co Substituted polycyclic pyridone derivative and prodrug thereof
SG11201804348SA (en) * 2015-12-15 2018-06-28 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
CN106589126A (zh) * 2016-12-07 2017-04-26 中国药科大学 一种抗人cd24抗体突变体的设计及其应用
CN111936517B (zh) 2018-01-26 2025-04-18 瑞泽恩制药公司 抗tmprss2抗体和抗原结合片段
US20210393786A1 (en) * 2018-07-26 2021-12-23 Purdue Research Foundation Small molecule ligand-targeted drug conjugates for anti-influenza chemotherapy and immunotherapy
TWI861205B (zh) * 2019-09-06 2024-11-11 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法

Similar Documents

Publication Publication Date Title
JP2023517236A5 (https=)
JP2023538369A5 (https=)
US11926657B2 (en) Neutralizing anti-influenza binding molecules and uses thereof
JP2023511956A5 (https=)
US10654915B2 (en) Antibodies useful in passive influenza immunization
JP2018503361A5 (https=)
CN105209071A (zh) 用于提高疗效的基于鼻内递送中和抗体的组合物和方法
JP6949012B2 (ja) Ｂ型肝炎表面抗原に対する抗体及びその使用
JP2024540226A5 (https=)
JP2021511043A5 (https=)
IL275884B1 (en) Human antibodies to influenza hemagglutinin
JP2021523138A5 (https=)
CN102216330B (zh) 用于病毒所致的疾病的抗体药物组合物
CN116234577A (zh) 用于治疗和预防covid-19的sars-cov-2抗体
JP2022535523A5 (https=)
JP2023502398A5 (https=)
JP2021529766A5 (https=)
JP2023506779A5 (https=)
JP2024529960A5 (https=)
JP2022553703A5 (https=)
JP2022502380A5 (https=)
WO2022019340A1 (ja) 抗体、及びその使用
RU2024114721A (ru) Композиции на основе антител к тау-белку, их лекарственные формы и способы их применения
JP2025511167A5 (https=)
HK40069730A (en) Neutralizing anti-influenza binding molecules and uses thereof